Cholesterol crystal induced arterial inflammation and destabilization of atherosclerotic plaque

European Heart Journal

Volumn 37, Issue 25, 2016, Pages 1959-1967

  Janoudi, Abed ^a   Shamoun, Fadi E ^b   Kalavakunta, Jagadeesh K ^a,c   Abela, George S ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b MAYO CLINIC   (United States)

^c Borgess Hospital   (United States)

Author keywords

Atherosclerosis; Cholesterol crystals; IL 1b; Vascular inflammation; Vulnerable patient; Vulnerable plaque

Indexed keywords

ANTIINFLAMMATORY AGENT; CANAKINUMAB; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN;

ARTERIAL INFLAMMATION; ATHEROSCLEROTIC PLAQUE; CHOLESTEROL ESTERIFICATION; DISEASE COURSE; HUMAN; MOLECULAR IMAGING; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SCANNING ELECTRON MICROSCOPY; VASCULITIS; ARTERITIS; FOAM CELL;

ARTERITIS; CHOLESTEROL; FOAM CELLS; HUMANS; LIPOPROTEINS, HDL; PLAQUE, ATHEROSCLEROTIC;

EID: 84977561328     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehv653     Document Type: Review

References (57)

1. WHO. Global atlas on cardiovascular disease prevention and control, World Health Organization; World Heart Federation; World Stroke Organization (editors). World Health Organization 2011; 164 p. http://whqlibdoc.who.int/ publications/2011/9789241564373-eng.pdf?ua=1 (accessed 29 July 2015).
2. Schaar JA, Muller JE, Falk E, Virmani R, Fuster V, Serruys PW, Colombo A, Stefanadis C, Ward Casscells S, Moreno PR, Maseri A, van der Steen AF. Terminology for high-risk and vulnerable coronary artery plaques. Report of a meeting on the vulnerable plaque, 17 and 18 June 2003, Santorini, Greece. Eur Heart J 2004;25: 1077-1082.
3. Abela GS, Aziz K. Cholesterol crystals rupture biological membranes and human plaques during acute cardiovascular events: A novel insight into plaque rupture by scanning electron microscopy. Scanning 2006;28:1-10.
4. Abela GS, Vedre A, Janoudi A, Huang R, Durga S, Tamhane U. Effect of statins on cholesterol crystallization and atherosclerotic plaque stabilization. Am J Cardiol 2011;107:1710-1717.
5. Abela GS, Aziz K, Vedre A, Pathak D, Talbott JD, DeJong J. Effect of cholesterol crystals on plaques and intima in arteries of patients with acute coronary and cerebrovascular syndromes. Am J Cardiol 2009;103:959-968.
6. Liu L, Gardecki JA, Nadkarni SK, Toussaint JD, Yagi Y, Bouma BE, Tearney GJ. Imaging the subcellular structure of human coronary atherosclerosis using microoptical coherence tomography. Nat Med 2011;17:1010-1014.
7. Patel R, Janoudi A, Vedre A, Aziz K, Tamhane U, Rubinstein J, Abela O, Berger K, Abela GS. Plaque rupture and thrombosis is reduced by lowering cholesterol levels and crystallization with ezetimibe and is correlated with FDG-PET. Arterioscler Thromb Vasc Biol 2011;31:2007-2014.
8. Frink RJ. Parallel cholesterol crystals: A sign of impending plaque rupture? J Invasive Cardiol 2010;22:406-411.
9. Duwell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind F, Abela GS, Franchi L, Nunez G, Schnurr M, Espevik T, Lien G, Fitzgerald KA, Rock KL, Moore KJ, Wright SD, Hornung V, Latz E. NLRP3 inflamasomes are required for atherogenesis and activated by cholesterol crystals that form early in disease. Nature 2010;464:1357-1361.
10. Sparrow CP, Parthasarathy S, Steinberg D. A macrophage receptor that recognizes oxidized low density lipoprotein but not acetylated low density lipoprotein. J Biol Chem 1989;264:2599-2604.
11. Kruth HS, Skarlatos SI, Gaynor PM, GambleW. Production of cholesterol-enriched nascent high density lipoproteins by human monocyte-derived macrophages is a mechanism that contributes to macrophage cholesterol efflux. J Biol Chem 1994; 269:24511-24518.
12. de la Llera Moya M, McGillicuddy FC, Hinkle CC, Byrne M, Joshi MR, Nguyen V, Tabita-Martinez J, Wolfe ML, Badellino K, Pruscino L, Mehta NN, Asztalos BF, Reilly MP. Inflammation modulates human HDL composition and function in vivo. Atherosclerosis 2012;222:390-394.
13. Saia F, Komukai K, Capodanno D, Sirbu V, Musumeci G, Boccuzzi G, Tarantini G, Fineschi M, Tumminello G, Bernelli C, Niccoli G, Coccato M, Bordoni B, Bezerra H, Biondi-Zoccai G, Virmani R, Guagliumi G; OCTAVIA Investigators. Eroded versus ruptured plaques at the culprit site of STEMI: in vivo pathophysiological features and response to primary PCI. JACC Cardiovasc Imaging 2015;8:566-575.
14. Kellner-Weibel G, Yancy PG, Jerome WG, Walser T, Mason RP, Phillips MC, Rothblat GH. Crystallization of free cholesterol in model macrophage foam cells. Arterioscler Thromb Vasc Biol 1999;19:1991-1998.
15. Varsano N, Fargion I, Wolf SG, Leiserowitz L, Addadi L. Formation of 3D cholesterol crystals from 2D nucleation sites in lipid bilayer membranes: implications for atherosclerosis. J Am Chem Soc 2015;137:1601-1607.
16. Zhao B, Song J, Chow WN, St Clair RW, Rudel LL, Ghosh S. Macrophagespecific transgenic expression of cholesteryl ester hydrolase significantly reduces atherosclerosis and lesion necrosis in Ldlr mice. J Clin Invest 2007;117: 2983-2992.
17. Chiba T, Ikeda M, Umegaki K, Tomita T. Estrogen-dependent activation of neutral cholesterol ester hydrolase underlying gender difference of atherogenesis in apoE2/2 mice. Atherosclerosis 2011;219:545-551.
18. Kellner-Weibel G, Jerome WG, Small DM, Warner GJ, Stoltenborg JK, Kearney MA, Corjay MH, Phillips MC, Rothblat GH. Effects of intracellular free cholesterol accumulation on macrophage viability: a model for foam cell death. Arterioscler Thromb Vasc Biol 1998;18:423-431.
19. Nissen SE, Tuzcu EM, Brewer HB, Sipahi I, Nicholls SJ, Ganz P, Schoenhagen P, Waters DD, Pepine CJ, Crowe TD, Davidson MH, Deanfield JE, Wisniewski LM, Hanyok JJ, Kassalow LM; ACAT Intravascular Atherosclerosis Treatment Evaluation (ACTIVATE) Investigators. Effect of ACAT inhibition on the progression of coronary atherosclerosis. N Engl J Med 2006;354:1253-1263.
20. Meuwese MC, de Groot E, Duivenvoorden R, Trip MD, Ose L, Maritz FJ, Basart DC, Kastelein JJ, Habib R, Davidson MH, Zwinderman AH, Schwocho LR, Stein EA; CAPTIVATE Investigators. ACAT inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia. The CAPTIVATE Randomized Trial. JAMA 2009;301:1131-1139.
21. Shiomi M, Ito T, Fujioka T, Tsujita Y. Age-associated decrease in plasma cholesterol and changes in cholesterol metabolism in homozygousWatanabe heritable hyperlipidemic rabbits. Metabolism 2000;49:552-556.
22. Kolodgie FD, Burke AP, Nakazawa G, Cheng Q, Xu X, Virmani R. Free cholesterol in atherosclerotic plaques: where does it come from? Curr Opin Lipidol 2007;18: 500-507.
23. Vedre A, Pathak DR, Crimp M, Lum C, Koochesfahani M, Abela GS. Physical factors that trigger cholesterol crystallization leading to plaque rupture. Atherosclerosis 2009;203:89-96.
24. Naghavi M. Preventive Cardiology: the SHAPE of the future. A Synopsis from the Screening for Heart Attack Prevention and Education (SHAPE) Task Force report. Herz 2007;32:356-361.
25. Oram JF, Lawn RM. ABCA1: The gatekeeper for eliminating excess tissue cholesterol. J Lipid Res 2001;42:1173-1179.
26. Wang N, Lan D, Chen W, Matsuura F, Tall AR. ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc Natl Acad Sci USA 2004;101:9774-9779.
27. Adams CWM, Abdulla YH. The action of human high density lipoprotein on cholesterol crystals. Atherosclerosis 1978;31:465-471.
28. Mohammadpour AH, Akhlaghi F. Future of Cholesterol ester transfer protein (CETP) inhibitors: a pharmacological perspective. Clin Pharmacokinet 2013;52: 615-626.
29. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature 2011;473:317-325.
30. Valente AJ, Irimpen AM, Siebenlist U, Chandrasekar B. OxLDL induces endothelial dysfunction and death via TRAF3IP2: Inhibition by HDL3 and AMPK activators. Free Radic Biol Med 2014;70:117-128.
31. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994;94:2494-2503.
32. Pasini AF, Anselmi M, Garbin U, Franchi E, Stranieri C, Nava MC, Boccioletti V, Vassanelli C, Cominacini L. Enhanced levels of oxidized low-density lipoprotein prime monocytes to cytokine overproduction via upregulation of CD14 and tolllike receptor 4 in unstable angina. Arterioscler Thromb Vasc Biol 2007;27:1991-1997.
33. Kleinbongard P, Heusch G, Schulz R. TNF alpha in atherosclerosis, myocardial ischemia/ reperfusion and heart failure. Pharmacol Ther 2010;127:295-314.
34. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006;440:237-241.
35. Tosato G, Jones KD. Interleukin-1 induces interleukin-6 production in peripheral blood monocytes. Blood 1990;75:1305-1310.
36. Gervois P, Kleemann R, Pilon A, Percevault F, Koenig W, Staels B, Kooistra T. Global suppression of IL-6-induced acute phase response gene expression after chronic in vivo treatment with the peroxisome proliferator-activated receptoralpha activator fenofibrate. J Biol Chem 2004;279:16154-16160.
37. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-843.
38. Samstad EO, Niyonzima N, Nymo S, Aune MH, Ryan L, Bakke SS, Lappegard KT, Brekke OL, Lambris JD, Damas JK, Latz E, Mollnes TE, Espevik T. Cholesterol crystals induce complement-dependent inflammasome activation and cytokine release. J Immunol 2014;192:2837-2845.
39. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM; IMPROVE-IT Investigators. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med 2015;372:2387-2397.
40. Lundberg B. Chemical composition and physical state of lipid deposits in atherosclerosis. Atherosclerosis 1985;56:93-110.
41. Nakamura S, Inami S, Murai K, Takano M, Takano H, Asai K, YasutakeM, ShimizuW, Mizuno K. Relationship between cholesterol crystals and culprit lesion characteristics in patients with stable coronary artery disease: an optical coherence tomography study. Clinc Res Cardiol 2014;103:1015-1021.
42. Tian J, Ren X, Vergallo R, Xing L, Yu H, Jia H, Soeda T, McNulty I, Hu S, Lee H, Yu B, Jang IK. Distinct morphological features of ruptured culprit plaque for acute coronary events compared to those with silent rupture and thin-cap fibroatheroma: a combined optical coherence tomography and intravascular ultrasound study. J Am Coll Cardiol 2014;63:2209-2216.
43. Loree HM, Kamm RD, Stringfellow RG, Lee RT. Effects of fibrous cap thickness on peak circumferential stress in model atherosclerotic vessels. Circ Res 1992;71: 850-858.
44. Stone GW, Maehara A, Lansky AJ, de Bruyne B, Cristea E, Mintz GS, Mehran R, McPherson J, Farhat N, Marso SP, Parise H, Templin B, White R, Zhang Z, Serruys PW; PROSPECT Investigators. A prospective natural-history study of coronary atherosclerosis. N Engl J Med 2011;364:226-235.
45. Nasiri M, Janoudi A, Vanderberg A, Frame M, Flegler C, Flegler S, Abela GS. Role of cholesterol crystals in atherosclerosis is unmasked by altering tissue preparation methods. Micros Res Tech 2015;78:969-974.
46. Lim RS, Suhalim JL, Miyazaki-Anzai S, Miyazaki M, Levi M, Potma EO, Tromberg BJ. Identification of cholesterol crystals in plaques of atherosclerotic mice using hyperspectral CARS imaging. J Lipid Res 2011;52:2177-2186.
47. Li H, El-Dakdouki MH, Zhu DC, Abela GS, Huang X. Synthesis of ß-cyclodextrin conjugated superparamagnetic iron oxide nanoparticles for selective binding and detection of cholesterol crystals. Chem Commun (Camb) 2012;48:3385-3387.
48. Blom DJ, Hala T, Bolognese M, Lillestol MJ, Toth PD, Burgess L, Ceska R, Roth E, Koren MJ, Ballantyne CM, Monsalvo ML, Tsirtsonis K, Kim JB, Scott R, Wasserman SM, Stein EA, for the DESCARTES Investigators. A 52-Week Placebo-Controlled Trial of evolocumab in hyperlipidemia. N Engl J Med 2014;370: 1809-1819.
49. Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes ES, Langslet G, Raal FJ, El Shahawy M, Koren MJ, Lepor NE, Lorenzato C, Pordy R, Chaudhari U, Kastelein JJ;ODYSSEY LONGTERM Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015;372: 1489-1499.
50. Ridker PM, Thuren T, Zalewski A, Libby P. Interleukin-1b inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J 2011; 162:597-605.
51. Everett BM, Pradhan AD, Solomon DH, Paynter N, Macfadyen J, Zaharris E, Gupta M, Clearfield M, Libby P, Hasan AA, Glynn RJ, Ridker PM. Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. Am Heart J 2013;166:199-207.
52. Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol 2013;61:404-410.
53. Hersberger M. Potential role of the lipoxygenase derived lipid mediators in atherosclerosis: leukotrienes, lipoxins and resolvins. Clin Chem Lab Med 2010;48: 1063-1073.
54. Greenwood AI, Pan J, Mills TT, Nagle JF, Epand RM, Tristram-Nagle S. CRAC motif peptide of the HIV-1 gp41 protein thins SOPC membranes and interacts with cholesterol. Biochim Biophys Acta 2008;1778:1120-1130.
55. Khunnawat C, Mukerji S, Havlichek D, Touma R, Abela GS. Cardiovascular manifestations in human immunodeficiency virus-infected patients. Am J Cardiol 2008; 102:635-642.
56. Abela GS, Aziz K. Cholesterol crystals cause mechanical damage to biological membranes: a proposed mechanism of plaque rupture and erosion leading to arterial thrombosis. Clin Cardiol 2005;28:413-420.
57. Abela GS. Cholesterol crystals piercing the arterial plaque and intima triggers local and systemic inflammation. J Clin Lipidol 2010;4:156-164.